A Phase 3 program of eloralintide in obstructive sleep apnea and obesity is registered
Phase IIIP1Primary public evidenceTrial registry record
NCT07369011 lists a start date of 10 February 2026 for a master protocol of Phase 3 placebo-controlled studies of once-weekly eloralintide in adults with moderate to severe obstructive sleep apnea and obesity or overweight. The registry lists 800 planned participants, 115 locations and primary completion in March 2028.
800
Planned participants, as recorded in the registry
March 2028
Primary completion date listed in the registry
Background and context
What the record describes
The record describes a master protocol with two independent studies. One (YSA1) enrols adults who cannot or will not use positive airway pressure (PAP) therapy. The other (YSA2) enrols adults who have used PAP for at least three months and plan to continue.
Who can take part
Adults need moderate to severe obstructive sleep apnea, an apnea-hypopnea index (AHI) of at least 15 on a study sleep test, and a BMI of at least 27. People with diabetes are excluded. There are two primary endpoints at week 64, percent change in body weight and change in AHI. Participation lasts about 76 weeks.
What the record does not say
No results are posted. The record does not say how the two sub-studies will be reported, or whether they will be analysed together.
Trial record: ClinicalTrials.gov NCT07369011, read on 2026-10-15. Registered plans can change.
P1Primary public evidenceTrial registry record.An official trial registration. A registration shows that a study exists; it does not show that the compound works.
